Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Bevacizumab + Deferred Aflibercept for Diabetic Macular Edema
NCT03321513Phase 3Completed
- Sponsor
- Jaeb Center for Health Research
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept, bevacizumab in diabetic macular edema (DME), sponsored by Jaeb Center for Health Research. Started Dec 2017; status: completed.
02
Drugs
afliberceptbevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03321513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321513.